These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 26205395

  • 1. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, Asami Y, Inoue T, Yoneda T.
    Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
    [Abstract] [Full Text] [Related]

  • 2. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E.
    Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [Abstract] [Full Text] [Related]

  • 4. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K, Ramirez L, Kukreja K, Venkatramani R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440
    [Abstract] [Full Text] [Related]

  • 5. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P.
    BMC Cancer; 2021 Jan 22; 21(1):89. PubMed ID: 33482769
    [Abstract] [Full Text] [Related]

  • 6. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.
    Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA.
    World J Surg Oncol; 2018 Sep 19; 16(1):191. PubMed ID: 30231890
    [Abstract] [Full Text] [Related]

  • 7. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.
    Ann Surg Oncol; 2015 Sep 19; 22(9):2860-8. PubMed ID: 26033180
    [Abstract] [Full Text] [Related]

  • 8. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.
    Clin Cancer Res; 2012 Aug 15; 18(16):4415-24. PubMed ID: 22711702
    [Abstract] [Full Text] [Related]

  • 9. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D'Arienzo A, Capanna R, Franchi A.
    J Clin Pathol; 2016 Mar 15; 69(3):240-7. PubMed ID: 26338802
    [Abstract] [Full Text] [Related]

  • 10. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL, Hansen RL, Jørgensen PH.
    Ugeskr Laeger; 2016 Sep 05; 178(36):. PubMed ID: 27593237
    [Abstract] [Full Text] [Related]

  • 11. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
    Abu-Zaid A, Alaqaili SI, Ahmad SO, Bin Hazzaa I, Alharbi H.
    Gulf J Oncolog; 2019 May 05; 1(30):67-75. PubMed ID: 31242985
    [Abstract] [Full Text] [Related]

  • 12. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.
    Eur J Cancer; 2017 May 05; 76():118-124. PubMed ID: 28324746
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T.
    BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567
    [Abstract] [Full Text] [Related]

  • 14. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 22; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.
    Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, Gelderblom H.
    Oncologist; 2019 Jul 22; 24(7):889-e421. PubMed ID: 31040253
    [Abstract] [Full Text] [Related]

  • 16. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 22; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 17. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU, Umer M, Khan Z, Saeed J, Siddiqui MA, Din NU.
    Ann Diagn Pathol; 2020 Apr 22; 45():151479. PubMed ID: 32088577
    [Abstract] [Full Text] [Related]

  • 18. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
    Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, Kamijo R.
    Pathol Oncol Res; 2019 Jan 22; 25(1):409-419. PubMed ID: 29159783
    [Abstract] [Full Text] [Related]

  • 19. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R.
    Eur J Surg Oncol; 2018 Sep 22; 44(9):1384-1390. PubMed ID: 29650420
    [Abstract] [Full Text] [Related]

  • 20. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H, Ishihara S, Toda Y, Oda Y.
    Med Mol Morphol; 2020 Mar 22; 53(1):1-6. PubMed ID: 31748824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.